EFFECTIVENESS AND TOXICITY DIFFERENCES BETWEEN THE USE OF REGIMEN CHEMOTHERAPY BLEOMYCIN-VINCRISTINE-MITOMYCIN-CISPLATIN AND BLEOMYCIN- VINCRISTINE-MITOMYCIN-CARBOPLATIN FOR THREE CYCLES IN PATIENTS CERVICAL CANCER SQUAMOUS CELL STADIUM IIB-IIIB IN SANGLAH GENERAL HOSPITAL DENPASAR BALI Research Article
Authors: R Noviyani , K Suwiyoga , Ing Budiana , K Tunas , Pa Indrayathi 
Published: October 2016

<p>ABSTRACT<br />Objectives: Medicines in the market need their security and their effectiveness monitored to ensure patient safety, which is called Clinical Testing<br />Stage IV. Cytotoxic medicines especially those for cervical cancer chemotherapy, particularly need to be monitored. These medicines include two<br />combinations: Bleomycin-vincristine-mitomycin-cisplatin (BOM-cisplatin) and bleomycin-vincristine-mitomycin-carboplatin (BOM-carboplatin).<br />Both these combinations are commonly used for cervical cancer treatments in Sanglah General Hospital. Up till now, there has not been adequate<br />data to differentiate between the two combinations. Therefore, we conducted the research to explore the relative effectiveness and toxicity of<br />both combinations. The assessment of both combinations can be seen using parameter squamous cell carcinoma (SCC) and tumor-mass. Toxicity<br />assessment of the chemotherapy can be seen by judging functions of the liver (serum glutamic oxaloacetic transaminase [SGOT], serum glutamic<br />pyruvic transaminase [SGPT]), kidneys (blood urea nitrogen [BUN], creatinine), and blood (leukocytes, hemoglobin) of patients.<br />Methods: The observational research with the cross-sectional method in Obstetrics and Gynecology Clinics in Sanglah General Hospital Denpasar<br />Bali. Research on both combinations was carried out between 2013 and 2015. The samples were obtained before the 1<br /> chemotherapy and after the<br />3<br />rd<br />st<br /> chemotherapy, by using consecutive sampling method. Prodia Clinical Laboratory carried out examinations on levels of SCC, while tumor-mass and<br />the other parameters were carried out by Clinical Pathology Laboratory Sanglah General Hospital. Data were analyzed with the paired t-test with 95%<br />confidence interval, using SPSS 17.0 for Windows.<br />Results: Samples used in this research was 12 patients who got combination BOM-cisplatin and 9 patients who got combination BOM-carboplatin.<br />In the group of BOM-cisplatin, there is no difference of content of leukocytes, hemoglobin, creatinine, BUN, SGOT, SGPT, and SCC before the<br />1<br />st<br /> chemotherapy and after the 3<br />rd<br /> chemotherapy (*p&gt;0.05). However, there are different levels of tumor mass before the 1<br /> chemotherapy and after<br />the 3<br /> chemotherapy (*p&lt;0.05). In the group of BOM-carboplatin, there are no differences in the levels of Creatinine, BUN, SGPT, SGOT, tumor mass,<br />and SCC (*p&gt;0.05). However, there are different levels of leukocytes and hemoglobin (*p&lt;0.05).<br />rd<br />Conclusion: The use of combination BOM-cisplatin can be said to be effective by the change of patients’ tumor-mass after undergoing chemotherapy.<br />The combination BOM-carboplatin is not effective because there were no changes in patients’ tumor-mass and patients’ levels of antigen SCC, and has<br />toxic effects on patients’ blood after undergoing chemotherapy.<br />Keywords: Effectiveness, Toxicity, Bleomycin-vincristine-mitomycin-cisplatin, Bleomycin-vincristine-mitomycin-carboplatin, Cervical cancer.<br />st</p>